Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug tame graft-versus-host disease when steroids fail?

NCT ID NCT05621733

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study follows about 140 people in Korea who have steroid-refractory graft-versus-host disease (GvHD) — a serious complication after a stem cell transplant where donor immune cells attack the recipient's body. Researchers are tracking how well the drug ruxolitinib (Jakavi) works and what side effects occur when it is used in real-world medical practice. The goal is to see if the drug's benefits seen in clinical trials hold up outside of a controlled research setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ruxolitinib (Jakavi), a drug that calms an overactive immune response
What this could lead to
If the drug performs well in everyday practice, it could confirm ruxolitinib as a reliable option for controlling severe GvHD when steroids fail.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

140 people

The number who actually took part.

Started

Apr 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are going to receive Jakavi® for the first time or those who are currently taking Jakavi® per clinical judgment

Ages

12 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label 2. Patients who are willing to provide written informed consent prior to study enrollment Exclusion Criteria: 1. Patients under 12 years old 2. Patients with contraindication according to locally approved label of Jakavi® 3. Patients who receive or are going to receive any investigational medicine during the observation period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft -versus-host-disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft -versus-host-disease

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    Jinju, Gyeongsangnam-do, 52727, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, Korea, 10408, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 02841, South Korea

  • Novartis Investigative Site

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    Busan, 48108, South Korea

  • Novartis Investigative Site

    Busan, 49241, South Korea

  • Novartis Investigative Site

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    Taegu, 41944, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.